Shefali Agarwal - 06 Dec 2021 Form 4 Insider Report for Epizyme, Inc.

Role
Executive Vice President, Chief Medical and Development Officer
Signature
/s/ John Weidenbruch, attorney-in-fact
Issuer symbol
N/A
Transactions as of
06 Dec 2021
Net transactions value
-$5,215
Form type
4
Filing time
07 Dec 2021, 18:03:56 UTC
Previous filing
18 Aug 2021
Next filing
28 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Sale $5,215 -1,780 -1.1% $2.93 163,004 06 Dec 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted under the Issuer's 2013 Stock Incentive Plan on December 6, 2021. The automatic sale of the reporting person's shares of Common Stock is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person.
F2 The reporting person acquired 1,277 shares of Common Stock under the Issuer's 2013 Employee Stock Purchase Plan on August 31, 2021.

Remarks:

Executive Vice President, Chief Medical and Development Officer